NCT05731258View on ClinicalTrials.gov

Observational of Adjuvant Treatment of Breast Cancer With Liposomal Doxorubicin Regimen

RecruitingOBSERVATIONAL
Enrollment

150

Participants

Timeline

Start Date

May 1, 2022

Primary Completion Date

October 31, 2027

Study Completion Date

October 31, 2032

Conditions
Breast CancerLiposomal DoxorubicinEfficacySafetyPostoperative Adjuvant Treatment
Interventions
DRUG

Liposomal doxorubicin containing regimen

Liposomal doxorubicin hydrochloride (PLD) 30-40mg/m2 D1 + other drugs (decided by investigators); All patients were treated with 4 cycles.

Trial Locations (1)

310009

RECRUITING

Second Affiliate Hospital of Zhejiang University, Hangzhou

All Listed Sponsors
lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER

NCT05731258 - Observational of Adjuvant Treatment of Breast Cancer With Liposomal Doxorubicin Regimen | Biotech Hunter | Biotech Hunter